Skip to evidence report

MAC.MDM.complement_resolving: Studies — page 13

How association tiers are defined — cell–trait and gene–trait

SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.

Cell–trait tiers

Cell–trait links
Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
Required for Specific or Relevant
The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
Specific (Tier 1)
Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
Relevant (Tier 2)
Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
Interpretation and report values
CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
Meta traits and individual traits
Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.

Gene–trait priorities (variant–tCRE–gene evidence)

Variant–tCRE–gene links
Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
Required genetic support
The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
Required cellular support
The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
High priority
Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
Medium priority
Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
Same-record evidence and aggregation
Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
Limits of interpretation
A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.

State · 1,931 full-atlas cells · all tissues.

Marker genes and cell annotation · Open this population in Cell Browser →

ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.

Rows 12,001–12,313 of 12,313; ranked by score descending. Equal values use name/identifier order.

Studies ranked for MAC.MDM.complement_resolving
#Trait / studyIndividual trait IDMean IC score
12001HypothyroidismGCST900186428.35e-05
12002IDP dMRI TBSS L1 Posterior limb of internal capsule LGCST900040948.35e-05
12003potassium (mean, inv-norm transformed)GCST904763078.33e-05
12004Type 2 diabetes, wide definitionFING000013838.25e-05
12005CPA1 levelsGCST904688368.16e-05
12006Pancreas fatGCST900166758.16e-05
12007Eye problems/disorders - None of the above | EyesightUKBB000002327.88e-05
12008BA-exvivo lh area entorhinalGCST900032207.86e-05
12009PDGF-BB levelsGCST904284307.78e-05
12010COVID-19 vaccinationGCST902556137.75e-05
12011Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T209ECGA0002097.73e-05
12012Hypo-osmolality and hyponatraemiaFING000006487.66e-05
12013Disorders of lacrimal systemFING000004417.63e-05
12014Inpatient record format - UK HES In Patient (2015 format) | Summary AdministrationUKBB000003647.62e-05
12015aparc-Desikan rh volume cuneusGCST900028057.58e-05
12016Hip minimal joint space widthGCST902813657.58e-05
12017Invitation to complete online 24-hour recall dietary questionnaire, acceptance | Online follow-up - Diet by 24-hour recallUKBB000003787.57e-05
12018Cardiovascular diseases (excluding rheumatic etc)FING000002557.42e-05
12019Corns and callosities (PheCode 700)GCST904761967.42e-05
12020Haemorrhoidal diseaseGCST900140337.40e-05
12021rfMRI amplitudes (ICA100 node 35)GCST900046237.40e-05
12022aparc-pial lh area postcentralGCST900031627.32e-05
12023Retention of urineFING000012577.32e-05
12024All dysplastic lesions of the cervix uteriFING000000607.04e-05
12025Body mass indexGCST900259946.99e-05
12026Benign neoplasm of colon | neoplasmsUKBB000000926.87e-05
12027BCAM/CDH5 ratioGCST903134696.78e-05
12028CES3 levelsGCST904687206.75e-05
12029FAM171B levelsGCST904691836.62e-05
12030Venous thromboembolismGCST903997446.46e-05
12031CPA1/PRSS2 ratioGCST903142066.45e-05
12032Takes medication for Diabetes/sugar?GCST904752686.39e-05
12033Cholesterol to Total Lipids in Medium VLDL percentageGCST904989266.39e-05
12034Weight (maximum, inv-normal transformed)GCST904764606.29e-05
12035Plasma mannonate* levels in chronic kidney diseaseGCST902654796.19e-05
12036TLR4 levelsGCST904708805.80e-05
12037Liver enzyme levels (gamma-glutamyl transferase)GCST900134075.72e-05
12038Cereal type: Biscuit cereal (e.g. Weetabix) (UKB data field 1468_2)GCST901329695.70e-05
12039Body mass indexGCST904281195.66e-05
12040X-08402 levelsGCST902435385.62e-05
12041Autorefraction - 3mm cylindrical power (left) | EyesightUKBB000000625.62e-05
12042Champagne or white wine consumption (glasses per month) (UKB data field 1578, 4418)GCST901329865.59e-05
12043FABP1/FABP2 ratioGCST903147505.50e-05
12044Gamma glutamyl transferase levelsGCST902786305.47e-05
12045Fruit intake (weighted GWA)GCST902672835.42e-05
12046Left ventricular end diastole inferior wall thicknessGCST902785155.41e-05
12047Random glucose levelsGCST902715575.40e-05
12048IDP dMRI TBSS MD Superior fronto-occipital fasciculus LGCST900040705.39e-05
12049Blood cell traits latent factor 22 (white cell)GCST905592645.30e-05
12050Prescriptions - anti-malarialUKBB000006635.28e-05
12051Prescriptions - quinine bisulfate | anti-malarialUKBB000006985.28e-05
12052Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T478ECGA0004785.28e-05
12053Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T40ECGA0000405.11e-05
12054Diastolic blood pressureGCST900187325.09e-05
12055TFF2 levelsGCST904708365.05e-05
12056BA-exvivo lh volume V2GCST900028455.04e-05
12057Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T27ECGA0000274.99e-05
12058Other disorders of breastFING000010184.84e-05
12059aparc-Desikan lh thickness lateraloccipitalGCST900034554.76e-05
12060X-12844 levelsGCST902005234.72e-05
12061Leg predicted mass (right) | Impedance measuresUKBB000003974.60e-05
12062Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T15ECGA0000154.56e-05
12063IDP dMRI TBSS L3 Anterior limb of internal capsule RGCST900041874.51e-05
12064Body mass index (BMI) | Impedance measuresUKBB000001044.44e-05
12065Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T18ECGA0000184.43e-05
12066Weight (minimum, inv-normal transformed)GCST904764664.39e-05
12067aparc-DKTatlas lh area postcentralGCST900032544.38e-05
12068Benign neoplasm: ColonFING000001714.37e-05
12069aparc-a2009s rh area S-calcarineGCST900034144.28e-05
12070All dysplastic lesions of the cervix uteri, vagina or vulvaFING000000614.22e-05
12071Leg fat-free mass (right) | Impedance measuresUKBB000003944.15e-05
12072COL4A1 levelsGCST904688184.05e-05
12073Hip circumference adjusted for BMIGCST900200284.03e-05
12074Body mass index (BMI) | Body size measuresUKBB000001034.01e-05
12075GlaucomaGCST904681294.01e-05
12076Leg fat mass (left) | Impedance measuresUKBB000003893.96e-05
120771-margaroyl-2-linoleoyl-GPC (17:0/18:2) metabolite levelGCST906160133.96e-05
12078Erectile dysfunctionGCST0069563.95e-05
12079Suicide or other Intentional self-harmFING000013453.93e-05
12080Cardiovascular delta age (difference between cardiac MRI-predicted and chronological age)GCST902397483.87e-05
12081Leg fat mass (right) | Impedance measuresUKBB000003903.84e-05
12082Weight (UKB data field 21002)GCST904681833.84e-05
12083Glucose | Blood biochemistryUKBB000002883.81e-05
12084Intraocular pressure (confirmatory factor analysis Factor 26)GCST903093603.77e-05
12085Smoking status (standard GWA)GCST902673023.76e-05
12086Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T207ECGA0002073.75e-05
12087T1 FreeSurfer DK rh superiorparietal thicknessGCST903857513.75e-05
12088Urinary incontinence (PheCode 599.4)GCST904761523.71e-05
12089BA-exvivo lh area BA3bGCST900032103.70e-05
12090Leg fat-free mass (left) | Impedance measuresUKBB000003933.67e-05
12091Number of correct matches in round | Pairs matchingUKBB000005323.61e-05
12092Type 2 diabetes with renal manifestations (PheCode 250.22)GCST904756703.60e-05
12093ObesityGCST0014753.57e-05
12094Colorectal cancerGCST900185883.55e-05
12095Principal component-derived dietary pattern 42GCST901330473.49e-05
12096Leg predicted mass (left) | Impedance measuresUKBB000003963.45e-05
12097Gamma glutamyltransferase levels (UKB data field 30730)GCST904680703.22e-05
12098Hearing difficulty with background noiseGCST902457753.18e-05
12099CELA3A/CTRC ratioGCST903140123.17e-05
12100Sphingomyelin (d17:1/16:0, d18:1/15:0, d16:1/17:0) levelsGCST902000173.14e-05
12101Age at first sexual intercourseGCST900000453.03e-05
12102Retinal detachments and defects | sense organsUKBB000007562.96e-05
12103Undecenoylcarnitine (C11:1) levelsGCST902002362.96e-05
12104Blood glucose levelsGCST900259862.88e-05
12105Breast cancerGCST904681172.86e-05
12106CXADR levelsGCST904689222.82e-05
12107Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T479ECGU0004792.81e-05
12108ICD10 N80: EndometriosisGCST904542132.81e-05
12109Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T36ECGA0000362.78e-05
12110Trunk fat mass (UKB data field 23128)GCST904681802.74e-05
12111Flat foot (PheCode 735.1)GCST904762482.72e-05
12112T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 14)GCST903205772.70e-05
12113IGFBPL1 levelsGCST904695332.63e-05
12114Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T13ECGA0000132.63e-05
12115Osteoarthritis of the hip or kneeGCST0070922.62e-05
12116Principal component-derived dietary pattern 32GCST901330372.58e-05
12117Eye autorefraction and astigmatism (confirmatory factor analysis Factor 24)GCST903093582.58e-05
12118Arm fat mass (left) | Impedance measuresUKBB000000432.57e-05
12119Other headache syndromesFING000010552.55e-05
12120aseg rh volume HippocampusGCST900026412.54e-05
12121Takes medication for enlarged prostate (Benign prostatic hyperplasia)?GCST904752622.46e-05
12122Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T14ECGA0000142.45e-05
12123Retinal detachment with retinal defect | sense organsUKBB000007542.44e-05
12124aseg global volume VentricleChoroidGCST900025982.36e-05
12125Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T438ECGU0004382.34e-05
12126TFF1 levelsGCST904708352.34e-05
12127Urea | Blood biochemistryUKBB000008852.34e-05
12128IDP T1 FAST ROIs R planum temporaleGCST900025422.30e-05
12129CA2/TGM2 ratioGCST903135822.29e-05
12130T1 CAT volume R RightThalamusGCST903840972.24e-05
12131Fracture of rib(s), sternum and thoracic spineFING000005582.21e-05
12132Whole body fat free mass (UKB data field 23101)GCST904281202.21e-05
12133Breast cancerGCST0049882.20e-05
12134Lysophosphatidylcholine (24:0) [sn2] levelsGCST900241872.20e-05
12135aparc-a2009s lh area G+S-subcentralGCST900033002.20e-05
12136Unspecified/other endometriosisFING000014042.18e-05
12137IDP T1 FAST ROIs R occ poleGCST900025462.16e-05
12138Beef consumption (UKB data field 1369)GCST901329972.11e-05
12139rfMRI amplitudes (ICA25 node 12)GCST900045792.07e-05
12140Dermatochalasis (PheCode 374.6)GCST904758942.06e-05
12141Whole body fat mass (UKB data field 23100)GCST904281212.05e-05
12142IDP T1 SIENAX CSF unnormalised volumeGCST900024292.02e-05
12143MUC13 levelsGCST904699632.00e-05
12144ADAM12 levelsGCST904682161.93e-05
12145IDP T1 SIENAX CSF normalised volumeGCST900024281.92e-05
12146Sleep apnea with BMI < 30GCST906247971.91e-05
12147MEGF9/MET ratioGCST903154181.89e-05
12148Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T5ECGA0000051.89e-05
12149Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T30ECGA0000301.85e-05
12150Subarachnoid haemorrhageFING000013391.84e-05
12151IDP dMRI TBSS MO Superior corona radiata LGCST900039771.84e-05
12152Spinal stenosis (PheCode 720)GCST904762331.80e-05
12153Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T11ECGA0000111.78e-05
12154Trigger fingerFING000013761.77e-05
12155Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T463ECGU0004631.68e-05
12156Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T233ECGA0002331.65e-05
12157KIRREL2 levelsGCST904696901.63e-05
12158UNC5D levelsGCST904710101.63e-05
12159IDP T1 FAST ROIs L caudateGCST900025491.62e-05
12160Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T7ECGA0000071.59e-05
12161potassium (maximum, inv-norm transformed)GCST904763041.58e-05
12162DTI TBSS L1 Posterior thalamic radiation LGCST903844571.58e-05
12163IDP dMRI TBSS ISOVF External capsule RGCST900045091.53e-05
12164MenorrhagiaFING000008081.53e-05
12165Breathing problems during period of job | Employment historyUKBB000001111.52e-05
12166Takes medication for acid reflux/GERD?GCST904753211.51e-05
12167Cysteine-glutathione disulfide levelsGCST901997841.44e-05
12168Attendance/disability/mobility allowance - None of the above | Other sociodemographic factorsUKBB000000591.43e-05
12169Arm fat mass (right) | Impedance measuresUKBB000000441.39e-05
12170Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T464ECGU0004641.39e-05
12171T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 76)GCST903206391.35e-05
12172Tibiofemoral angleGCST902702631.32e-05
121731-palmitoyl-2-oleoyl-GPE (16:0/18:1) metabolite levelGCST906164031.30e-05
12174Addison's diseaseGCST900118711.29e-05
12175Hypermetropia (PheCode 367.8)GCST904758821.29e-05
12176EDA2R levelsGCST904690671.29e-05
12177Sphingomyelin (d18:2/23:0, d18:1/23:1, d17:1/24:1) levelsGCST902000331.25e-05
12178CPA1/CTRB1 ratioGCST903142031.23e-05
12179Use of antiglaucoma preparations and mioticsFING000014091.22e-05
12180Alcohol intake versus 10 years previously | AlcoholUKBB000000241.19e-05
12181Cataract | sense organsUKBB000001201.18e-05
12182Internal derangement of knee (PheCode 835)GCST904762821.18e-05
12183Descending aorta diameterGCST902673911.14e-05
12184LAMP3/PRSS8 ratioGCST903152751.14e-05
12185PLA2G1B levelsGCST904702461.13e-05
12186Lysophosphatidylcholine (24:0) [sn2] levelsGCST900254261.11e-05
12187ROBO2/SFTPD ratioGCST903157851.11e-05
12188Hallux valgus (Bunion) | musculoskeletalUKBB000002991.11e-05
12189Glucose (fasting status unknown, mean, inv-norm transformed)GCST904753321.05e-05
12190aparc-Desikan rh thickness cuneusGCST900034831.04e-05
12191Average log acceleration during the five least active hours of the dayGCST900614311.03e-05
12192DiverticulitisGCST904681259.92e-06
12193Plantar fascial fibromatosisFING000011699.85e-06
12194High-grade serous epithelial ovarian cancerGCST902441689.72e-06
12195Bell pepper likingGCST900947039.58e-06
12196CPB1/REG1A ratioGCST903142129.57e-06
121973-amino-2-piperidone levelsGCST902001889.57e-06
12198Weight (mean, inv-normal transformed)GCST904764639.31e-06
12199chloride (maximum, inv-norm transformed)GCST904751929.26e-06
12200Urea levels (UKB data field 30670)GCST904681089.10e-06
122011-palmitoyl-2-linoleoyl-gpc (16:0/18:2) levelsGCST902003309.06e-06
12202Forearm length to body height ratioGCST902702578.59e-06
12203chloride (mean, inv-norm transformed)GCST904751948.58e-06
12204HippSubfield rh volume CA1-headGCST900026968.45e-06
12205Indolelactate levelsGCST902435078.43e-06
12206Unstable angina pectorisFING000014058.24e-06
12207A body shape indexGCST0122317.97e-06
12208Other benign neoplasms of skinFING000009717.97e-06
12209Diabetes (confirmatory factor analysis Factor 28)GCST903093627.95e-06
12210aparc-DKTatlas lh thickness cuneusGCST900035437.91e-06
12211Prostate cancerGCST902747147.87e-06
12212Diabetes (standard GWA)GCST902672787.84e-06
12213IDP dMRI TBSS MD Superior fronto-occipital fasciculus RGCST900040697.44e-06
12214Number of treatments/medications taken | MedicationsUKBB000005427.42e-06
12215Cancer code, self-reported: prostate cancer (UKB data field 20001_1044)GCST900419057.12e-06
12216SDHB levelsGCST904705617.11e-06
12217ROBO2/SCARF2 ratioGCST903157846.58e-06
12218CardiomyopathyGCST903997056.14e-06
12219Ascending aorta strainGCST902673886.03e-06
12220Vegetables likingGCST900948625.93e-06
12221Treatment speciality of consultant (recoded) - Trauma & orthopaedics | Summary AdministrationUKBB000008375.76e-06
12222CPA1/CPB1 ratioGCST903142025.70e-06
12223T1 FreeSurfer BA rh BA3a exvivo thicknessGCST903855635.70e-06
12224Operative procedures - Insertion of prosthetic replacement for lens NEC | Summary OperationsUKBB000005835.65e-06
12225Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T8ECGA0000085.51e-06
12226Treatment/medication code - lansoprazole | MedicationsUKBB000008485.35e-06
12227DTI TBSS MD Posterior limb of internal capsule RGCST903845905.32e-06
12228IDP dMRI ProbtrackX OD str lGCST900044735.25e-06
12229Chronic Kidney Disease, Stage III (PheCode 585.33)GCST904761285.19e-06
12230Pain and other conditions associated with female genital organs and menstrual cycleFING000011365.04e-06
12231Blood urea nitrogen levelsGCST902786234.99e-06
12232Calculus of kidney and ureterFING000002364.77e-06
12233Prostate cancerGCST902747164.75e-06
12234SEPTIN8 levelsGCST904705784.63e-06
12235Benign neoplasm: Colon, unspecifiedFING000001724.53e-06
12236DTI TBSS L1 External capsule RGCST903844604.47e-06
12237Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T4ECGA0000044.34e-06
12238Frailty (Factor 6 - Disability)GCST906240524.23e-06
12239HippSubfield rh volume CA3-bodyGCST900027024.15e-06
12240Lung function (FEV1/FVC)GCST0074314.01e-06
12241Operative procedures - Unspecified diagnostic endoscopic examination of colon | Summary OperationsUKBB000005913.99e-06
12242Aneurysm of iliac artery (PheCode 442.2)GCST904759953.94e-06
12243Benign neoplasm of colon, rectum, anus and anal canalFING000001553.76e-06
12244GSTT2B levelsGCST904694153.55e-06
12245aparc-Desikan lh thickness cuneusGCST900034493.52e-06
12246Other disorders of eyelids (PheCode 374)GCST904758903.52e-06
12247N6,N6-dimethyllysine levels in chronic kidney diseaseGCST902575293.50e-06
12248SERPINI2 levelsGCST904706033.28e-06
12249PNLIPRP1 levelsGCST904702733.24e-06
12250Psoriatic arthritis vs Cutaneous psoriasisGCST902439573.19e-06
12251Non-mucinous epithelial ovarian cancerGCST902441673.09e-06
12252Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T445ECGU0004452.76e-06
12253Prostate cancerGCST904751852.73e-06
12254Arm fat percentage left (UKB data field 23123)GCST904681572.65e-06
12255Butternut squash likingGCST900947182.56e-06
12256aparc-DKTatlas rh thickness cuneusGCST900035742.49e-06
12257rfMRI connectivity (ICA100 edge 951)GCST900058042.42e-06
12258Malignant neoplasm of prostate, excluding all cancers (controls excluding all cancers)FING000007702.41e-06
12259COL6A3 levelsGCST904688212.29e-06
12260Frequency of drinking alcohol | Alcohol useUKBB000002602.17e-06
12261Phospholipids to Total Lipids in Small LDL percentageGCST904996902.15e-06
12262Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T10ECGA0000102.11e-06
12263Own or rent accommodation lived in - Own outright (by you or someone in your household) | HouseholdUKBB000006232.00e-06
12264Prostate cancerGCST904281171.79e-06
12265Total thigh muscle volume z-scoreGCST902673561.67e-06
12266Arm fat percentage right (UKB data field 23119)GCST904681581.66e-06
12267Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T39ECGA0000391.63e-06
12268Volume of right anterior amygdaloid areaGCST904750031.61e-06
12269Cancer code, self-reported: breast cancer (UKB data field 20001_1002)GCST900418861.61e-06
12270DDR1/SFTPD ratioGCST903144431.57e-06
12271Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T232ECGA0002321.44e-06
12272Campesterol levelsGCST901997251.30e-06
12273aparc-a2009s rh thickness Pole-occipitalGCST900037181.26e-06
12274HMOX2 levelsGCST904694661.24e-06
12275Elevated prostate specific antigen [PSA] (PheCode 796)GCST904762771.22e-06
12276Prostate cancerGCST900186851.11e-06
12277Leg fat percentage right (UKB data field 23111)GCST904681751.06e-06
12278CD59 levelsGCST904686391.04e-06
12279Cancer of prostate (PheCode 185)GCST904755919.83e-07
12280Leg fat percentage left (UKB data field 23115)GCST904681749.06e-07
12281Leg fat percentage (left) | Impedance measuresUKBB000003919.03e-07
12282Breathing problems responsible for leaving job | Employment historyUKBB000001126.96e-07
12283aparc-a2009s lh volume S-centralGCST900029696.62e-07
12284CD3 on Terminally Differentiated CD4+ T cellGCST900018446.60e-07
12285Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T9ECGA0000096.43e-07
12286aseg lh volume Lateral-VentricleGCST900026166.26e-07
12287Uterine fibroidsGCST904619586.00e-07
12288HippSubfield rh volume Whole-hippocampusGCST900027115.60e-07
12289Joint pain (confirmatory factor analysis Factor 14)GCST903093485.51e-07
12290aparc-a2009s rh area G-pariet-inf-SupramarGCST900033965.47e-07
12291Other heart diseasesFING000010574.04e-07
12292Operative procedures - Fibreoptic endoscopic snare resection of lesion of colon | Summary OperationsUKBB000005793.98e-07
12293COQ7 levelsGCST904688313.34e-07
12294Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T37ECGA0000372.86e-07
12295TIGIT levelsGCST904708652.60e-07
12296IDP dMRI ProbtrackX L1 str lGCST900042692.54e-07
12297Thoracic aortic aneurysmFING000013572.35e-07
12298Breast cancerGCST0100982.01e-07
12299GAST levelsGCST904693071.62e-07
12300Leg fat percentage (right) | Impedance measuresUKBB000003921.59e-07
12301T1 CAT volume L LateralOccipitalCortexinferiordivisionGCST903840441.55e-07
12302Blood urea nitrogen (BUN, maximum, inv-norm transformed)GCST904751621.24e-07
12303Arm fat percentage (right) | Impedance measuresUKBB000000468.66e-08
12304Arm fat percentage (left) | Impedance measuresUKBB000000458.22e-08
12305GPHA2 levelsGCST904693897.48e-08
12306Hypertensive Heart DiseaseFING000006395.78e-08
12307GPLD1 levelsGCST900868905.37e-08
12308Benign lipomatous neoplasmFING000001464.01e-08
12309BA-exvivo lh volume BA3aGCST900028373.39e-08
12310Prostate cancerGCST0060853.08e-08
12311Normotensive glaucomaFING000008922.33e-08
12312Body fat percentage | Impedance measuresUKBB000001022.03e-08
12313Long-standing illness, disability or infirmity | General healthUKBB000004092.04e-09